title: Deep brain stimulation affects conditioned and unconditioned anxiety in different brain areas.
abstract: Deep brain stimulation (DBS) of the nucleus accumbens (NAc) has proven to be an effective treatment for therapy refractory obsessive-compulsive disorder. Clinical observations show that anxiety symptoms decrease rapidly following DBS. As in clinical studies different regions are targeted, it is of principal interest to understand which brain area is responsible for the anxiolytic effect and whether high-frequency stimulation of different areas differentially affect unconditioned (innate) and conditioned (learned) anxiety. In this study, we examined the effect of stimulation in five brain areas in rats (NAc core and shell, bed nucleus of the stria terminalis (BNST), internal capsule (IC) and the ventral medial caudate nucleus (CAU)). The elevated plus maze was used to test the effect of stimulation on unconditioned anxiety, the Vogel conflict test for conditioned anxiety, and an activity test for general locomotor behaviour. We found different anxiolytic effects of stimulation in the five target areas. Stimulation of the CAU decreased both conditioned and unconditioned anxiety, while stimulation of the IC uniquely reduced conditioned anxiety. Remarkably, neither the accumbens nor the BNST stimulation affected conditioned or unconditioned anxiety. Locomotor activity increased with NAc core stimulation but decreased with the BNST. These findings suggest that (1) DBS may have a differential effect on unconditioned and conditioned anxiety depending on the stimulation area, and that (2) stimulation of the IC exclusively reduces conditioned anxiety. This suggests that the anxiolytic effects of DBS seen in OCD patients may not be induced by stimulation of the NAc, but rather by the IC.
authors.affiliation: Department of Psychiatry, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands. addyvandijk@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: van Dijk
authors.forename: M
authors.initials: M
authors.lastname: Klanker
authors.forename: N
authors.initials: N
authors.lastname: van Oorschot
authors.forename: R
authors.initials: R
authors.lastname: Post
authors.forename: R
authors.initials: R
authors.lastname: Hamelink
authors.forename: M G P
authors.initials: MG
authors.lastname: Feenstra
authors.forename: D
authors.initials: D
authors.lastname: Denys
mesh_terms: D000818:Animals; D001007:Anxiety / Q000503:physiopathology / Q000628:therapy*; D001921:Brain / Q000503:physiopathology*; D002421:Caudate Nucleus / Q000503:physiopathology; D003214:Conditioning, Classical; D046690:Deep Brain Stimulation; D020772:Internal Capsule / Q000503:physiopathology; D008297:Male; D018782:Maze Learning / Q000502:physiology; D009043:Motor Activity / Q000502:physiology; D009714:Nucleus Accumbens / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar
references.citation: Curr Psychiatry Rep. 2011 Aug;13(4):274-82
references.pmid: 21505875
references.citation: Mol Psychiatry. 2010 Jan;15(1):64-79
references.pmid: 18490925
references.citation: Prog Neurobiol. 2003 Jun;70(2):83-244
references.pmid: 12927745
references.citation: Int J Neuropsychopharmacol. 2005 Sep;8(3):391-401
references.pmid: 15801987
references.citation: Eur J Pharmacol. 2003 Feb 28;463(1-3):199-216
references.pmid: 12600711
references.citation: Arch Gen Psychiatry. 1994 Jan;51(1):62-70
references.pmid: 8279930
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):314-22
references.pmid: 1660103
references.citation: Cereb Cortex. 2011 Jul;21(7):1667-73
references.pmid: 21127016
references.citation: Proc Natl Acad Sci U S A. 2012 May 29;109(22):8764-9
references.pmid: 22586125
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):906-14
references.pmid: 17376577
references.citation: Behav Neurosci. 2006 Apr;120(2):324-36
references.pmid: 16719697
references.citation: Psychiatry Res. 1997 Mar 14;74(1):25-33
references.pmid: 10710160
references.citation: Behav Brain Funct. 2009 Sep 23;5:40
references.pmid: 19775445
references.citation: Nat Rev Neurosci. 2012 Sep;13(9):651-8
references.pmid: 22850830
references.citation: Behav Brain Res. 1993 Jul 30;56(1):115-8
references.pmid: 8397853
references.citation: J Neurosci Methods. 1985 Aug;14(3):149-67
references.pmid: 2864480
references.citation: PLoS One. 2009;4(4):e5346
references.pmid: 19399175
references.citation: Behav Brain Res. 2008 Nov 21;193(2):243-7
references.pmid: 18586053
references.citation: J Neurosci. 2012 Jan 4;32(1):254-63
references.pmid: 22219287
references.citation: J Neurosci Methods. 2011 Nov 15;202(2):113-8
references.pmid: 21565219
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):105-35
references.pmid: 19693004
references.citation: Brain Res. 1996 Mar 25;713(1-2):79-91
references.pmid: 8724978
references.citation: Arch Gen Psychiatry. 2010 Oct;67(10):1061-8
references.pmid: 20921122
references.citation: J Neurosurg. 2004 Oct;101(4):682-6
references.pmid: 15481726
references.citation: Acta Psychiatr Scand. 2003 Apr;107(4):275-82
references.pmid: 12662250
references.citation: Psychopharmacologia. 1971;21(1):1-7
references.pmid: 5105868
references.citation: Behav Neurosci. 1998 Apr;112(2):379-86
references.pmid: 9588484
references.citation: J Neurosci. 2011 Jul 13;31(28):10392-402
references.pmid: 21753016
references.citation: Behav Brain Res. 2011 Mar 17;218(1):174-83
references.pmid: 21115068
references.citation: Front Neurosci. 2011 Sep 09;5:102
references.pmid: 21927595
references.citation: Am J Psychiatry. 2011 Dec;168(12):1255-65
references.pmid: 21865528
references.citation: Psychopharmacology (Berl). 2011 Feb;213(2-3):465-73
references.pmid: 20945065
references.citation: Behav Brain Res. 2001 Nov 1;125(1-2):141-9
references.pmid: 11682105
references.citation: Psychopharmacology (Berl). 2006 May;186(1):122-32
references.pmid: 16568282
references.citation: Psychiatry Res. 2006 Mar 31;146(2):137-47
references.pmid: 16507346
references.citation: Arch Gen Psychiatry. 1996 Jul;53(7):595-606
references.pmid: 8660126